Primary endpoint exceeded in Phase-2 trial of brain cancer patients

A treatment for patients with glioblastoma multiforme, the most common form of brain cancer, exceeded its primary endpoint in a Phase-2 efficacy trial, the sponsor, Apogenix GmbH of Heidelberg, announced.